Provexis PLC (PXS)
Industry Drug Manufacturers - Specialty & Generic
This stock can be held in an Investment ISA, SIPP and Investment Account
Sell
0.605p
Buy
0.70p
-0.0175p (-2.61%)
Prices updated at 12 Dec 2025, 13:00 GMT
| Prices minimum 15 mins delay
Prices in GBX
Provexis PLC is engaged in developing and licensing the proprietary Fruitflow, which is a heart-health functional food ingredient for the functional food sector.
Important documents: Please ensure that you have read the Pre-sale Illustrations document & Doing Business with Fidelity document (incorporating the Fidelity Client Terms) and
- Key stats
- Price
- Fair value
- Dividends
- News
- Financials
- Valuation
- Profile
Profit margins
Valuation
Profit margins data table
Year | Gross margin (%) |
|---|---|
| 2025 | 41.24 |
| 2024 | 35.39 |
| 2023 | 75.51 |
| 2022 | 89.18 |
| 2021 | 90.28 |
| 2020 | 89.72 |
| 2019 | 84.66 |
| 2018 | 90.18 |
| 2017 | 95.81 |
| 2016 | 100.00 |
| 2015 | 100.00 |
Valuation data table
Year | Price / Sales |
|---|---|
| 2025 | 11.54 |
| 2024 | 12.60 |
| 2023 | 36.95 |
| 2022 | 40.69 |
| 2021 | 35.42 |
| 2020 | 46.11 |
| 2019 | 37.03 |
| 2018 | 15.44 |
| 2017 | 37.94 |
| 2016 | 80.63 |
| 2015 | 69.73 |
Price/Forward earnings (YTD)
-
Returns
Debt profile
Returns data table
Year | Return on assets (%) |
|---|---|
| 2025 | -59.96 |
| 2024 | -87.24 |
| 2023 | -39.05 |
| 2022 | -18.53 |
| 2021 | -38.71 |
| 2020 | -87.29 |
| 2019 | -116.51 |
| 2018 | -155.37 |
| 2017 | -183.27 |
| 2016 | -132.85 |
| 2015 | -86.84 |
Debt profile data table
| Year | Financial leverage |
|---|---|
| 2025 | 0.78 |
| 2024 | 0.69 |
| 2023 | 0.71 |
| 2022 | 0.75 |
| 2021 | 0.78 |
| 2020 | 0.58 |
| 2019 | 0.57 |
| 2018 | 0.53 |
| 2017 | 0.34 |
| 2016 | 0.47 |
| 2015 | 0.58 |
The figures shown in the Profit Margins table EBITDA column are quoted in the currency of the stock selected.
